An interventional study of MagPro R30 with robotic arm in Post Traumatic Stress Disorder (PTSD), sponsored by The University of Texas Health Science Center at San Antonio. Recruiting at 1 site in United States. Open to participants aged 12 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by The University of Texas Health Science Center at San Antonio · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Stress Disorders, Post-Traumatic by The University of Texas Health Science Center at San Antonio — 8 open to participants now, 8 under way, none of them phase 3. Stress Disorders, Post-Traumatic · The University of Texas Health Science Center at San Antonio.
Among the 27 studies in Stress Disorders, Post-Traumatic by The University of Texas Health Science Center at San Antonio, this one is the 20th largest by planned enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2026, is one of 20 with no phase, and was the 25th registered.
2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →8 of the 27 studies in Stress Disorders, Post-Traumatic by The University of Texas Health Science Center at San Antonio are open now, in 1 country. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–65
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.
This study: 12 Years to 20 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 4 1
First in 2008; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 69 across 2,203 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 49 across the 25 interventional studies, 52 across the 2 observational. Of the 19 that completed or were terminated, 9 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
The University of Texas Health Science Center at San Antonio is the lead sponsor of 445 studies on the registry; 89 are open to participants now.
Of its 65 completed or terminated interventional studies of FDA-regulated products, 35 (54%) have results posted.
4 of the studies in Stress Disorders, Post-Traumatic by The University of Texas Health Science Center at San Antonio that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05423444The University of Texas Health Science Center at San AntonioNeural Connectivity During Therapy for Adolescent PTSD | 2027-02-28 |
| NCT07351305The University of Texas Health Science Center at San AntonioNon-Trauma Intervention to Treat PTSD for Veterans and Service Members Suffering From a TBI | 2027-03 |
| NCT07401225The University of Texas Health Science Center at San AntonioTMS for PTSD in Youth | 2027-06-01 |
| NCT07667309The University of Texas Health Science Center at San AntonioThe Effects of Stellate Ganglion Block Sleep in U.S. Active Duty Service Members and Veterans Receiving Prolonged Exposure Therapy for PTSD | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 27 studies in Stress Disorders, Post-Traumatic by The University of Texas Health Science Center at San Antonio, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to test whether transcranial magnetic stimulation, or TMS, is an acceptable and helpful treatment for ongoing symptoms of posttraumatic stress syndrome disorder (PTSD) in 12-20 year olds. Ongoing PTSD refers to symptoms that continue after completing trauma-focused psychotherapy. About 1 in 4 patients need additional help to overcome PTSD after completing psychotherapy. Currently, scientists do not know the best way to help adolescents with persistent PTSD, and this study will test TMS as a possible treatment, and hopefully lead to future studies including more people.
Trauma is a common occurrence among youth. Almost 60% of American youths experience a traumatic event before age 18, such as physical or sexual abuse, sudden loss of caregivers, or witnessing violence in the community or the home. Distress after a significantly traumatic event is to be expected, but for some youths, symptoms of posttraumatic stress disorder (PTSD) linger for months or years, and can become chronic if left untreated. Symptoms of PTSD can include upsetting memories, avoidance of reminders, and emotional numbing, and other symptoms. These symptoms can create difficulties for family relationships, friendships, and schoolwork. Currently, the most effective treatment for PTSD is talk therapy (trauma-focused psychotherapy). However, sometimes young people continue to have symptoms of PTSD after completing talk therapy, and it is currently not known the best way to help with these persistent symptoms.
In this study, the total length of time participants will be involved in the study is about 16-weeks. During that time, participants will be asked to attend approximately 6 research visits and 10 treatment visits, for a total of 16 visits. The 6 research visits include a screening visit, an interview visit, 2 MRI visits, and 2 follow-up visits. The screening, interview, and follow-up visits can be completed virtually, over zoom. The study will include 2 MRI visits and 10 treatment visits. Virtual follow-up visits will be conducted 1 and 3 months after completion of treatment and will include interviews and questionnaires about participants symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each treatment visit will take about 1.5 hours. Participants will receive up to 4 TMS treatment sessions during the visit, with each session lasting about 10-minutes. After the TMS sessions, there will be a brief visit with a psychotherapist.
Device: MagPro R30 with robotic arm
TMS will be delivered to the right anterior dorsolateral frontal cortex. The accelerated protocol consists of 1,800 TMS pulses per session, delivered at intensity ranges designed to deliver depth-corrected E-fields of 80-95 volts/meter. The exact intensity will be determined when the participant's treatment plan is developed. Once a patient's TMS treatment plan has been created, it will be used for every treatment session for that participant.
Side Effects of TMS treatment
number of side effects reported per participant
Time frame: Day 1 of treatment through Day 30
Number of Adverse Events
Number of adverse events experienced by study participants through the treatment phase of the study
Time frame: Day 1 of treatment through Day 30
Completion rate of Treatment
Number of participants that completed the TMS treatment
Time frame: Day 1 of treatment through Day 30
Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5)(CAPS-5)
The CAPS-5 score range for total symptom severity is 0 to 80, calculated by summing the severity ratings (0-4) for 20 PTSD symptoms, with higher scores indicating greater severity; scores below 31-33 often suggest subclinical or non-diagnostic levels, while scores above this range can indicate probable PTSD.
Time frame: Baseline to 90 days
Assessment of Depression using Patient Health Questionnaire-9 (PHQ-9)
Patients rate 9 common depressive symptoms (e.g., feeling down, trouble sleeping, low energy, poor appetite, concentration issues, feeling bad about self, restlessness/slowed down, thoughts of being better off dead/hurting self). Scoring: Each symptom gets 0-3 points, totaling 0-27. A lower score indicates less depression.
Time frame: Baseline to Day 30
Plan to share: Undecided — requests for data will be considered on a case-by-case basis
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.
Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 12 months is below that.
Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stress Disorders, Post-Traumatic →
The University of Texas Health Science Center at San Antonio →